NCT01618435

Brief Summary

The average life expectancy in Denmark is increasing resulting in an increasing part of the population having age-related disease, ex lumbar spinal stenosis (LSS). LSS causes constriction of the nerves in the lumbar spine resulting in pain in the legs and lower back, especially when standing and walking, known as neurogenic claudication(Goh KJ FAU - Khalifa et al.). LSS occurs in a combination of degenerative changes in the lower back, including hypertrophy of the ligamentum flavus, arthrosis of the facet joints and bulging of the disc. Current treatment of LSS is varied ranging from non-operative conservative treatment to operation. Operative intervention shows very good results according to physical ability and pain(Christensen FB et al.;Hee HT and Wong;McGregor AH FAU - Hughes and Hughes;Xu et al.), but the most optimal treatment is still debated. Nevertheless, a decompression and, if needed, a spinal fusion is recommended.(Ausman). Clinical improvement including decrease of pain, improved ADL-function and an increased quality of life are parameters of highest interest and the purpose of an operation is clear: Making sufficient room for the affected nerves. In addition fusion is desired achieving stability avoiding a new compression of the nerves. Studies attending these issues find a correlation between fusion and clinical outcome, why obtained fusion of the affected levels are very important(Andersen et al.;Andersen et al.;Girardo et al.;Kornblum MB FAU - Fischgrund et al.). P-15, bound to Anorganisk Bone Mineral (ABM), called i-FACTOR®, shows fusion superiority, no side effects and no risk of transferring disease(Thorwarth et al. 5648-57;Thorwarth et al. 789-95;Wenz, Oesch, and Horst 1599-606;Scarano et al. 318-24;Kubler et al. 171-79) why the investigators find this material suited for fusion surgery in the elderly. To the investigators knowledge this is the first prospective study comparing fusion rates and postoperative clinic with i-FACTOR vs allograft in older patients operated with decompression and spondylodesis because of spinal stenosis due to degenerative spondylolisthesis. Hypothesis: There are no difference in the clinical parameters measured by ODI and fusion rates comparing i-FACTOR® and allograft in non-instrumented posterolateral spondylodesis-operations in patients 60 years and older.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
108

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Mar 2012

Longer than P75 for phase_3

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 8, 2012

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 13, 2012

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
4.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2018

Completed
Last Updated

September 7, 2016

Status Verified

September 1, 2016

Enrollment Period

1.3 years

First QC Date

May 8, 2012

Last Update Submit

September 5, 2016

Conditions

Keywords

Fusion surgeryDegenerative olisthesisi-FACTORODISpinal stenosis

Outcome Measures

Primary Outcomes (1)

  • The clinical effect of i-FACTOR® versus allograft in non-instrumented posterolateral spondylodesis operation in the elderly with spinal stenosis due to degenerative spondylolisthesis measured by ODI

    24 months postoperative

Secondary Outcomes (1)

  • The clinical effect of i-FACTOR® versus allograft in non-instrumented posterolateral spondylodesis operation in the elderly with spinal stenosis due to degenerative spondylolisthesis assessed by fusion rates

    12 months postoperative

Study Arms (2)

Fusion, allograft

ACTIVE COMPARATOR

Allograft used for fusion in the operation site

Biological: i-FACTOR

Fusion, i-FACTOR

EXPERIMENTAL

i-FACTOR used for fusion in the operation site

Biological: i-FACTOR

Interventions

i-FACTORBIOLOGICAL

i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion

Also known as: i-FACTOR®putty, Cerapedics, USA. CE-brand 0086
Fusion, allograftFusion, i-FACTOR

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Spinal stenosis, olisthesis grade 1-2 (\>3 mm), facet joint arthrosis and flavus hypertrophia verified by a mr-scan and x-ray including maximally 2 levels ranging from L1-S1.
  • A score of 6 and more on Konno´s "History of Examination Characteristic".
  • Signed informed content.

You may not qualify if:

  • Any disease demanding obligate thromboprophylaxis treatment, including mechanical valve, (DVT with cancer/thrombophilia, AMI, apoplexia cerebri, TCI, valve-operation)\< 3 months, coronar metal stent \< 6 weeks and coronar drug eluted/coated stent \< 12 months.
  • Atrial fibrillation and one of the following: Mitral stenosis, valveprothesis and apoplexia cerebri/TCI.
  • Atrial fibrillation and two of the following: Heart insufficient, HT, DM, age \> 75 years, EF \< 35 %.
  • Known cancer in the axial skeleton.
  • Ongoing chemotherapy.
  • Reduced distance of walking due to non-spinal related causes.
  • Candidate for more than two-level intervention.
  • Dementia assessed by the MMSE
  • ASA 3+4
  • Age below 60 years.
  • Missed 3 months of conservative treatment without success
  • The use of steroids and bisphosphonates.
  • Prior radiotherapy to the lower back.
  • Haematologic disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Sygehuslillebaelt

Middelfart, DK, 5500, Denmark

Location

Rygkirurgisk sektor Middelfart

Middelfart, Region Syddanmark, 5500, Denmark

Location

MeSH Terms

Conditions

Spinal Stenosis

Interventions

Fibrinogen

Condition Hierarchy (Ancestors)

Spinal DiseasesBone DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

Acute-Phase ProteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsBlood Coagulation FactorsProtein PrecursorsBiological Factors

Study Officials

  • Michael K Jacobsen, MD

    Rygkirurgisk sektor Middelfart

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

May 8, 2012

First Posted

June 13, 2012

Study Start

March 1, 2012

Primary Completion

June 1, 2013

Study Completion

May 1, 2018

Last Updated

September 7, 2016

Record last verified: 2016-09

Locations